Recurrent Melanoma Terminated Phase 2 Trials for Semaxanib (DB06436)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00006003SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedTreatment